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Chemical Toxicity of Red Cells
by Sergio Piomelli*
Exposure to toxic chemicals may result in alterations of red cell function. In certain cases,
the toxic effect requires a genetic predisposition and thus affects only a restricted number of
individuals; in other instances, the toxic effect is exerted on the hematopoietic system ofevery
person.
Glucose-6-phosphate dehydrogenase deficiency is probably the most widespread genetic
disorder. It is observed at highest frequency in populations from subtropical countries as a
result ofits selective advantage vis A vis falciparum malaria. The gene controlling this enzyme
is located on the X-chromosome; thus, the defect is sex-linked. Individuals with a genetic defect
ofthis enzyme are extremely susceptible to hemolysis, when exposed to oxidant drugs (such as
certain antimalarials and sulfonamides) because ofthe inability oftheir red cells to regenerate
NADPH.
Lead poisoningresults in profound effects on the process ofheme synthesis. Among the steps
most sensitive to lead toxicity are the enzyme 8-aminolevulinic acid dehydratase and the
intramitochondrial step that leads to the incorporation of iron into protoporphyrin. By these
mechanisms, in severe lead intoxication there is an accumulation of large amounts of
8-aminolevulinic acid (a compound with inherent neurotoxicity), and there are abnormalities
ofmitochondrial function in all cells ofthe body. Individuals living in an industrialized society
are unavoidably exposed to some environmental lead. Recent evidence indicates that, even at
levels ofexposure which do not increase the blood lead level above values presently considered
normal, abnormalities of heme synthesis are clearly detectable.
The red cell is subject to a variety oftoxic effects
by chemicals. For some toxic effects the red cell is
the primary target, but in other cases it acts as an
innocent bystander, in the sense that, while the
toxic effect of the chemical may be obvious by
analysis of the red cell, its function and ability to
survive remain largely unaffected. While some
chemicals affect the red cells of all the individuals
exposed, others exert their effects only in certain
individuals.
Two examples ofchemical toxicity to the red cells
will be discussed in this report: the susceptibility to
drug-induced hemolysis in glucose-6-phosphate de-
hydrogenase (G6PD) deficiency (1) and the hema-
tological effects of lead poisoning (2). These two
cases of chemical toxicity to the red cell have been
the objects ofstudies in our laboratory and provide
clear illustrations of different aspects of chemical
toxicity to the red cell. The toxicity of some
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chemicals injures only the red cells and exclusively
in G6PD-deficient individuals; on the other hand,
the toxicity of lead involves practically all the
tissues of all the individuals exposed. While toxic
effects of lead are detectable in the red cell at
extremely low levels of exposure (3-5), from a
clinical point of view the damages to other tissues
are more significant; in children, for example,
neurological toxicity severe to the point of death
may occur before the clinical effects on the red cell
(anemia) become obvious.
G6PD Deficiency
This genetic defect is probably the most common
one in humans; it has been estimated that it affects
more than 300 million individuals (1). There are
several mutants of G6PD which yield a variety of
syndromes. This discussion, however, will focus
only on the two most common ones, GdB - and
GdA-(6). Theclinicalmanifestationsassociatedwith
the common types of G6PD deficiency consist of
65episodes ofbrisk hemolysis, shortly after exposure
to a drug or other redox compound. The clinical
history almost invariably reveals exposure either to
drugs like primaquine, sulfonamides, or furadantin
(to cite those most commonly used) or to chemicals
such as naphthalene. Hemolysis may also occur
during infections such as hepatitis (7) or during
chemical imbalance of the internal milieu, such as
diabetic acidosis (8). The toxic effects are direct on
the circulating red cells, which literally burst in the
circulation, releasing all of their hemoglobin con-
tent. Very rapidly, the hemoglobin binding protein,
haptoglobin, is saturated, and hemoglobin is spilled
in the urine.
The sequence of events at the cellular level can
be reproduced easily in the laboratory, by exposing
red cells of G6PD-deficient and normal individuals
to an oxidant, such as acetylphenylhydrazine. While
in all normal red cells there is some precipitation of
hemoglobin, in the G6PD-deficient cells this is
extreme (9). This phenomenon (called Heinz-body
formation) is observed also in vivo during the acute
hemolytic phase, when Heinz bodies can be seen in
the circulation for a short period, before the cells
burst and are cleared. The mechanism by which the
normal red cell counteracts oxidant stimuli utilizes
reduced glutathione as the hydrogen donor. The
regeneration of reduced glutathione is assured by
the chain of two enzymes: glutathione peroxidase
and reductase, both ofwhich are operative in G6PD
deficiency. In the red cell, the exclusive source of
NADPH, the substrate for glutathione reductase,
is the reaction catalyzed by G6PD (an additional
NADPH is generated by the subsequent step
catalyzed by 6-phosphogluconate dehydrogenase,
which utilizes 6-phosphogluconate, a product of
G6PD). In G6PD-deficient red cells, the concentra-
tion of reduced glutathione becomes rapidly inade-
quate, as soon as the concentration of NADPH
becomes rate-limiting (10). Thus, extensive per-
oxidation ofthe membrane and ofhemoglobin itself
results from oxidative insults. This leads to the
formation ofHeinz bodies in vivo and to consequent
intravascular hemolysis.
The peculiar racial distribution ofG6PD deficiency,
which is observed primarily among populations
from subtropical areas, led to the suggestion by
Motulsky that this genetic trait was maintained at
such high levels by the selective pressure of
falciparum malaria. The world maps of G6PD
deficiency and offalciparum malaria appear, in fact,
almost identical (11).
A series of classical pedigree studies by Child,
Zinkam, et al., shortly after the discovery of the
relationship between drug-induced hemolysis and
G6PD deficiency, led to the demonstration that the
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gene for G6PD is located on the X-chromosome
(12). This observation was further substantiated by
the demonstration ofa close linkage between G6PD
deficiency and colorblindness, another gene whose
location of the X-chromosome is well established
(13). The location of the gene for G6PD on the
X-chromosome has clarified the genetics of sex-
linkage, to the point that nowadays detailed map-
pings of the X-chromosome are available (14).
It was soon noted that the degree of enzyme
deficiency was different between Caucasians and
Africans (15). Electrophoresis of the enzyme re-
veals that the common (wild) type moves slowly
electrophoretically(thisisdesignatedasGdB+)(16).
Among Caucasian deficients, the defective enzyme
was found to have identical electrophoretic mobili-
ty, but grossly decreased activity. [This defective
mutant is designated GdB- or Gd-Mediterranean
(6), referring to its high frequency among Mediter-
ranean populations]. Among African individuals,
the majority have the common GdB+ enzyme; how-
ever, many (in certain areas of Africa as many as
40%) exhibit an enzyme of faster electrophoretic
mobility, designated GdA. Among these individu-
als, approximately half exhibited normal enzyme
activity (GdA+), while the other half exhibited
reduced enzyme activity (GdA-) (6). The two most
frequently encountered types of G6PD-deficient
mutant are therefore the GdB- and GdA-, among
Caucasians and Africans, respectively. Many other
mutants of G6PD have been described, some
associated with decreased activity and some not;
none of these, however, occurs at as high a fre-
quency as GdB- and GdA-. These two common
defective enzymes are different from each othernot
only in electrophoretic mobility, but also in the
level of enzyme activity and its clinical conse-
quences (1).
Table 1 summarizes the various possible geno-
types, taking into consideration not only the differ-
ences between sexes, but also in the levels of
activity between the GdB- and GdA- mutants.
In heterozygous females, whether of the B- or
A- type, the reduced level of activity stems from
the simultaneous presence in the circulation oftwo
Table 1. Possible genotypes of G6PD deficiency.
B- A-
Male
XY = Hemizygote = Normal 100% 100%
X-Y = Hemizygote = Abnormal 0-5% 5-15%
Female
XX = Homozygote = Normal 100% 100%
X-X = Heterozygote = Intermediate 20-80% 10-90%
X-X- = Homozygote = Abnormal 0-5% 5-15%
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one defective, which can be identified by appropri-
ate staining technique (17). This finding led to the
development ofthe theory ofgene dosage compen-
sation (18), later confirmed by a variety of other
techniques, which states that in any given cell of
females only one of the two X-chromosomes is
active. In the case of a woman heterozygous for
G6PD deficiency, those red cells descending from a
precursor cell in which the active chromosome
carries the Gd- gene are enzyme-deficient, while
the remaining red cells are normal. It is then
possible for a heterozygous-deficient woman to
undergo hemolysis, despite a substantial enzyme
level in her red cells (40-80% of normal), since the
defective cells are just as susceptible to oxidative
stress by chemicals or other agents as those from a
homozygous-deficient man; however, her normal
cells are resistant to hemolysis. Therefore, when a
heterozygous female is exposed to an offending
chemical, hemolysis can be abrupt, with hemoglo-
binuria and jaundice, but it is always self-limiting
and ceases as soon as the entire subpopulation of
deficient cells has been destroyed.
In homozygous males, the severity of hemolysis
induced by chemical toxicity can be very different,
depending on whether the defect in enzyme is
severe, as in GdB- individuals, or moderate, as in
GdA- individuals. In GdB- males the hemolysis
upon exposure to a toxic chemical can be fulminat-
ing, with extreme anemia to levels as low as 1-2 g/dl
ofhemoglobin, and may be fatal. In these individu-
als, there may be anear-instantaneous intravascular
destruction of all circulating erythrocytes, with
massive hemoglobinuria. On the other hand, in
GdA- males, hemolysis is also abrupt and severe,
often with hemoglobinuria, but the anemia never
reaches extremely low values and it ceases in a few
days, even when the exposure to the toxic chemical
continues. This apparent paradox has been shown
to result from the "age-dependency" of G6PD.
Marks and Johnson first noticed that in individuals
with reticulocytosis, the red cell G6PD activity was
increased (19). Red cells can be separated into
cohorts of progressively increasing age on discon-
tinuous density gradients (20). Serial measurements
of enzyme activity in red cell fractions of different
ages have shown that G6PD activity decays
exponentially with a t1/2 of 60 days in normal red
cells. However, in GdA- red cells, the enzyme
activity decays faster, with a t1/2 of 16 days and in
GdB- red cells the enzyme activity decays ex-
tremely rapidly, with a t1/2 of a few hours (21).
Quantitative measurements of G6PD with these
techniques have shown that in both GdA- and
GdB- the enzyme activity ofthe youngest red cells
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is as high as in the normal young red cells. The
enzymatic defect in the red cells in both cases,
therefore, results from the synthesis ofan unstable
enzyme, and not from a failure of the synthetic
rate. It is thus understandable how, in the case of
GdA- males, the anemia is self-limiting. In these
individuals, exposure to oxidant chemicals, in fact,
results in destruction only of the aged red cells.
Once these are removed from the circulation, the
remaining younger cells have adequate enzyme
activity to resist hemolysis. Even ifthe exposure to
the offending agent persists, the anemia improves,
since the newly formed red cells have normal
enzyme activity. In the case ofthe GdB- males, in
whom only a very small percentage of the young
cells have adequate enzyme activity, hemolysis,
which affects nearly all circulatingcells, is fulminat-
ing, and it may be fatal unless prompt transfusion
of non-G6PD-deficient blood is given (22).
The fact that G6PD deficiency stems from the
formation ofa highly unstable enzyme explains also
why the enzyme defect (and the inherent suscepti-
bility to chemical toxicity) is limited to the red cells
and to the cells of the lens of the eyes. These cells
lack a nucleus, and the ability of synthesizing
protein; any loss of enzyme cannot therefore be
compensated by an accelerated turnover. In all
other cells ofthe body, the existence of the appro-
priate machinery for protein synthesis permits the
maintenance of a normal level of enzyme (in the
case of GdA- individuals) or at least a substantial
level (20-25% of normal, in the case of GdB-
individuals) (15).
Our knowledge of the genetics and biochemistry
of G6PD deficiency has provided a clue to the
different susceptibility of individuals, within the
same ethnic group and even the same family, to the
toxicity of some chemicals. In the case of this
genetic defect, a rational scientific basis has been
furnished for the centuries-old observation by phy-
sicians that there is an "individual variability" in
the toxicity of certain chemicals.
Lead Poisoning
The chemical toxicity of lead results primarily
from its affinity for the SH groups (23). Its effects
are therefore extended to a variety of body func-
tions, for which the integrity of SH groups in the
proteins are essential. Additionally, lead is known
to have an affinity for mitochondria and to inhibit a
number of mitochondrial functions (24).
Lead is an ubiquitous contaminant ofthe modern
environment as a result ofits extensive mining and
ofthe utilization of a variety ofits compounds. The
largest single source oflead contamination is in the
67form of its alkyls, primarily used as gasoline
additives (24).
To have an approximate idea of the degree of
environmental contamination by lead, it is useful to
look at the blood lead content ofhuman populations.
[Lead in the blood is almost exclusively present in
the red cells (25).] The blood lead content repre-
sents that fraction ofPb which is present in the soft
tissues; an additional fraction ofthe total body Pb is
stored in the bones (23). Geophysical considerations
indicated that the lead content in the blood of
humans in the "natural" state (that is, without
man-made contamination) should be on the order of
0.2 ,ug/dl ofblood (28). Studies ofone "unacculturated"
population have recently revealed an average blood
lead of 0.8 ,ug/dl, essentially of the same order of
magnitude as predicted (27). A study from our
laboratory of a remote Himalayan population has
revealed a slightly higher, but still low, average
blood Pb of3.2 ,ug/dl (28). By contrast, in American
populations, there is a gradient of blood Pb levels,
with a progressive increase in average values from
rural to suburban to urban populations. In urban
populations, the average blood Pb level ranges
between 15 and 25 ,ug/dl (24). The blood lead levels
indicate the extent to which lead has permeated the
human body, in the present society.
Lead toxicity is particularly dangerous to chil-
dren whose nervous system is more vulnerable
than that of adults, at comparable levels of expo-
sure. Besides being more susceptible to its toxicity,
children retain and absorb more lead, through a
higher respiratory rate. Additionally, children in-
gest more lead, through their normal hand-to-
mouth (thumb-sucking) activities, which result in
the intake of lead-containing dust (29). A particu-
larly dangerous source of lead for children is
peeling paint, which in pre-World War II housing
has a very high content oflead. Since all sources of
lead are additive, it is not surprising that inner-city
children, who are subject to higher pollution and
are most likely to live in old and run-down housing,
are at the greatest risk of lead intoxication. This is
compounded by the fact that the simultaneous
nutritional deficit increases both lead absorption
and lead toxicity (30).
The hematological effects of lead toxicity are
obvious in the circulating red cells and result both
from a direct effect of lead and from its toxicity in
the bone marrow at the time ofred cell production.
Two steps in the pathway of heme synthesis are
very sensitive to lead: (1) the cytoplasmic enzyme,
5-aminolevulinic acid dehydratase, which converts
two molecules of &-aminolevulinic acid into porpho-
bilinogen, and (2) the mitochondrial enzyme
ferrochelatase, which inserts an atom of Fe at the
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center ofthe ring ofprotoporphyrin IX. It must be
noted that abnormalities of heme synthesis are
easily detectable in the red cells, because of all
tissues this is the easiest to sample. However, the
inhibition of heme synthesis is not unique to the
erythropoietic tissue, since heme is the universal
respiratory pigment and a constituent of the
respiratory chain of all cells, the cytochrome sys-
tem.
The enzyme 8-aminolevulinic acid dehydratase is
exquisitely sensitive to the effects oflead. Hernberg
and co-workers have demonstrated an inhibition of
this enzyme at the blood lead levels well below
those considered "normal" for Western populations
(3). Their studies indicate that there is no threshold
blood lead level for this inhibitory effect. The
inhibitory effect is so pronounced that for instance
at blood lead levels of 16 ptg/dl, the enzyme activity
is already reduced to 50% of its potential. [The
maximum potential of the enzyme in any given
individual can be established by exposing its red
cells to an SH reagent such as dithiothreitol (31).]
Inhibition of 8-aminolevulinic acid dehydratase
results in an accumulation of its substrate, 5-
aminolevulinic acid (a compound associated with a
variety of neurotoxic effects), and it is reflected by
an increased urinary excretion. As the activity of
the enzyme declines exponentially with an increas-
ing blood Pb level (3), this is paralleled by an
exponential rate ofincrease of5-aminolevulinic acid
in the urine (5) (Fig. 1).
The inhibition of the enzyme ferrochelatase by
lead probably results from the effect of lead on the
transmitochondrial transport of iron, more than
from a direct effect on the enzyme itself (32).
Whatever the precise mechanism ofthis manifesta-
tion of lead toxicity, during erythropoiesis it pro-
duces an accumulation of protoporphyrin (a pig-
ment nonfunctional from the respiratory point of
view) in the heme pocket of the hemoglobin.
Protoporphyrin is initially formed as the free-base,
but during the circulation of the red cell, rapidly
binds Zn (33) to form Zn-protoporphyrin (34). The
fluorescence of protoporphyrin (35) and Zn-
protoporphyrin (36) has been utilized to devise
simple techniques that permit its detection and
thus the rapid screening ofchildren for lead poison-
ing (36).
Currently, the definition of the Center for Dis-
ease Control recommends medical attention for
lead poisoning for all children with a blood Pb level
> 30 ,ug/dl, accompanied by a red cell protoporphy-
rin level > 50 ,ug/dl. Initial studies, which demon-
strated the exponential increase of protoporphyrin
with a linear increase in blood Pb level, focussed on
children with ahigh (> 40 ,ug/dl) blood Pb level (35).
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FIGURE 1. Relationship between blood Pb and parameters of
heme synthesis. (Top) Erythrocyte 8-aminolevulinic acid
dehydratase (8-ALAD). Exponential decline of activity de-
termined by Hernberg, et al., (3). No measurements were
obtained below blood Pb 5 ,ug/dl; the dotted part ofthe line is
theextrapolationtobloodPb = 0(logb-ALAD = 2.274 - 1.018
blood Pb). (Middle) Urinary 8-aminolevulinic acid (8-ALA).
Exponential increase in urinary excretion determined by
Selander and Cramer (5). No measurements were obtained
below blood Pb 5 ,ug/dl; the dotted part of the line is the
extrapolationtobloodPb = 0(logb-ALA = -1.0985 + 0.0157
blood Pb). (Bottom) Erythrocyte protoporphyrin (EP). Ex-
ponential increase oferythrocyte protoporphyrin determined
by Piomelli, et al., (28). Measurements were obtained from
blood Pb = 2,ug/dl. The dashed line indicates lack ofincrease
belowbloodPb = 14.5,ug/dl(logEP = 1.014 + 0.018bloodPb).
Recently, studies of children with blood Pb level <
30 ,ug/dl (i.e., in the range accepted as normal) have
shown that the threshold blood Pb level for the
increase in red cell protoporphyrin is between 14
and 17 ,ug Pb/dl (4). These values are well below the
average blood Pb level ofmost populations ofurban
children. These observations indicated that damage
of an essential mitochondrial function, to a degree
which results in the accumulation of a substrate,
occurs at previously unsuspected low levels of
exposure to lead. Since heme synthesis is a general
function of all cells, detection of its abnormality in
the red cell reflects a widespread injury to other
tissues.
As techniques of detection become more refined,
it is clear that the level of exposure to lead which
induces demonstrable significant damage will be-
come progressively lower. Apart from biochemical
alterations of the red cells, it has recently been
shown that children may exhibit neuropsychological
disturbances at levels of exposure lower than
previously suspected (33). As our knowledge ofthe
biochemical basis ofpathology deepens, alterations
ofspecificenzymesystems areprogressivelyidentified
as the specific mechanism ofclinical symptoms. For
instance, the "saturnine gout" reflects the inhibi-
tion of guanine aminohydrolase (38); the "periph-
eral neuropathy" oflead workers reflects the inhibi-
tion of aminocyclase (39); the "Monday morning
colic" reflects the defect in cytochrome P-450, an
essential component ofthe mixed liver oxidase (40).
As these correlations between pathology and its
biochemical basis become more apparent, it be-
comes difficult to assume that the increased blood
lead level of urban populations and the detectable
inhibition of essential biochemical systems is an
unavoidable and harmless result of industrializa-
tion.
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